Nunes H, Humbert M, Capron F, Brauner M, Sitbon O, Battesti J-P, Simonneau G, Valeyre D
UPRES EA 2363, Service de Pneumologie, Hôpital Avicenne, Assistance Publique-Hôpitaux de Paris, Université Paris 13, 125 rue de Stalingrad, 93009 Bobigny, France.
Thorax. 2006 Jan;61(1):68-74. doi: 10.1136/thx.2005.042838. Epub 2005 Oct 14.
Pulmonary hypertension (PH) is a rare complication of sarcoidosis, although it is not uncommon in advanced disease.
A retrospective series of 22 sarcoidosis patients (16 men) of mean (SD) age 46 (13) years with PH was divided into two groups depending on the absence (stage 0: n = 2, stage II: n = 4, stage III: n = 1) or presence (n = 15) of radiographic pulmonary fibrosis at the time of PH diagnosis.
In both groups PH was moderate to severe and there was no response to acute vasodilator challenge. In non-fibrotic cases no other cause of PH was found, suggesting a specific sarcoidosis vasculopathy, although no histological specimens were available. In cases with fibrosis there was no correlation between haemodynamics and lung volumes or arterial oxygen tensions, suggesting other mechanisms for PH in addition to pulmonary destruction and hypoxaemia. These included extrinsic arterial compression by lymphadenopathies in three cases and histologically proven pulmonary veno-occlusive disease in the five patients who underwent lung transplantation. Ten patients received high doses of oral prednisone for PH (stage 0: n = 1, stage II: n = 4 and stage IV: n = 5); three patients without pulmonary fibrosis experienced a sustained haemodynamic response. Survival of the overall population was poor (59% at 5 years). Mortality was associated with NYHA functional class IV but not with haemodynamic parameters or with lung function.
Two very different phenotypes of sarcoidosis combined with PH are observed depending on the presence or absence of pulmonary fibrosis. PH is a severe complication of sarcoidosis.
肺动脉高压(PH)是结节病的一种罕见并发症,尽管在晚期疾病中并不少见。
回顾性分析22例结节病合并PH的患者(16例男性),平均(标准差)年龄46(13)岁,根据PH诊断时有无影像学肺纤维化分为两组(无纤维化组:0期n = 2例,II期n = 4例,III期n = 1例;有纤维化组:n = 15例)。
两组患者的PH均为中度至重度,对急性血管扩张剂激发试验均无反应。在无纤维化病例中,未发现其他导致PH的原因,提示存在特定的结节病血管病变,尽管未获取组织学标本。在有纤维化的病例中,血流动力学与肺容积或动脉血氧张力之间无相关性,提示除了肺破坏和低氧血症外,还有其他导致PH的机制。其中包括3例因淋巴结病导致的外在动脉受压,以及5例接受肺移植患者经组织学证实的肺静脉闭塞性疾病。10例患者因PH接受了高剂量口服泼尼松治疗(0期:n = 1例,II期:n = 4例,IV期:n = 5例);3例无肺纤维化的患者出现了持续的血流动力学反应。总体人群的生存率较差(5年生存率为59%)。死亡率与纽约心脏协会(NYHA)心功能IV级相关,但与血流动力学参数或肺功能无关。
根据有无肺纤维化,观察到结节病合并PH有两种截然不同的表型。PH是结节病的一种严重并发症。